PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

76 percent of patients on oral JAK1/JAK2 inhibitor plus DMARDS achieve ACR20 response at week 12

Baricitinib demonstrates dose-dependent efficacy in active RA

2012-06-08
(Press-News.org) Berlin, Germany, June 8 2012: Data from a Phase IIb study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, show that 76% of patients with active rheumatoid arthritis (RA) receiving either 4mg or 8mg of baricitinib, an oral JAK1/JAK2 inhibitor, plus stable methotrexate (MTX) achieved ACR20* response compared with 41% of placebo-treated patients (p≤0.001) at 12 weeks. The 4mg and 8mg doses of baricitinib demonstrated statistical superiority to placebo in all clinical outcomes measured, including ACR20/50/70*, DAS28**-CRP and DAS28-CRP END


ELSE PRESS RELEASES FROM THIS DATE:

Novel brain imaging technique explains why concussions affect people differently

2012-06-08
June 8, 2012 — (Bronx, NY) — Patients vary widely in their response to concussion, but scientists haven't understood why. Now, using a new technique for analyzing data from brain imaging studies, researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found that concussion victims have unique spatial patterns of brain abnormalities that change over time. The new technique could eventually help in assessing concussion patients, predicting which head injuries are likely to have long-lasting neurological consequences, ...

Smoking negatively affects response to anti-TNF treatment in patients with rheumatoid arthritis

2012-06-08
Berlin, Germany, June 8 2012: A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, reinforces current thinking that smoking negatively affects treatment response in rheumatoid arthritis (RA) patients treated with anti-tumour necrosis factor (anti-TNF) drugs. This American study, the largest of its kind, followed 2,811 treatment naïve patients initiated onto anti-TNF therapy. Of the study group, 19% (n=521) were smokers and 81% (n=2,290) were non-smokers. Smokers had significantly higher scores on the Clinical Disease ...

Lung changes are present in nearly half of ACPA positive RA patients at disease onset

2012-06-08
Berlin, Germany, June 8 2012: A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that lung changes in association with anti-citrullinated protein autoantibody (ACPA) status are a primary manifestation of rheumatoid arthritis (RA). Study findings show that 51% of RA patients (n=105) had identifiable lung changes (as measured by high resolution computer tomography [HRCT]) as compared to 28% of healthy controls (n=43). In addition, ACPA presence – but not smoking status – was associated with HRCT changes. This ...

Obesity negatively predicts minimal disease activity achievement in patients with PSA

2012-06-08
Berlin, Germany, June 8 2012: According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with psoriatic arthritis (PsA) who are starting anti-tumour necrosis factor (anti-TNF) treatment and adhere to a hypocaloric diet have a significantly greater chance of achieving minimal disease activity (MDA, an important measure of disease activity) at six months compared to those on a standard diet. The results of an Italian study of 138 obese PsA patients demonstrated that those who achieved a ≥10% weight ...

Patients with PsA treated with ustekinumab are twice as likely to achieve acr20 vs. placebo

2012-06-08
Berlin, Germany, June 8 2012: A new Phase III study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that patients with active psoriatic arthritis (PsA) treated with Ustekinumab (UST) 90mg were more than twice as likely to achieve the study's primary endpoint, ACR20* at 24 weeks, than those treated with placebo (49.5% vs 22.8%). 42.4% of patients treated with UST 45mg were also more likely to achieve ACR20 at 24 weeks compared to placebo. Significant improvements were also seen with UST 45mg and 90mg in ACR50* (24.9% ...

Early menopause predicts a milder form of rheumatoid arthritis

2012-06-08
Berlin, Germany, June 8 2012 : A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that early menopause predicts a milder form of rheumatoid arthritis (RA). New insights on factors influencing RA are good news for sufferers of the chronic inflammatory disease that currently affects over 2 million women in Europe. 1,2 The study, based on 134 incident RA cases, found that patients aged over 45 years with a history of early menopause were 50% less likely to develop severe RA (16% versus 35%) and more likely to develop ...

Rabbit risk score can help rheumatologists identify patients at high risk of infection

2012-06-08
Berlin, Germany, June 8 2012: Results of a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, suggest that the newly developed RABBIT Risk Score, which calculates the risk of serious infections in patients with rheumatoid arthritis (RA) who are treated with anti-tumour necrosis factor drugs (anti-TNFs) or conventional disease modifying anti-rheumatic drugs (DMARDs) is a valid and effective tool for rheumatologists to predict risk of serious infection. The German study used data from 2,603 patients enrolled in the RABBIT ...

13.7 million young adults stayed on or joined their parents' health plans in 2011

2012-06-08
June 8, 2012, New York, NY—In 2011, 13.7 million young adults ages 19 to 25 stayed on or joined their parents' health plans, including 6.6 million who would likely not have been able to do so before passage of the Affordable Care Act, according to a new Commonwealth Fund report. However, not all young adults have parents with health plans they can join, and many still experience gaps in coverage and face medical bill problems and medical debt. Nearly two of five (39%) young adults ages 19 to 29 went without health insurance at some time in 2011, and more than one-third ...

Parcel2Go Helping Small Businesses to Beat Royal Mail Price Increase

2012-06-08
Small firms feeling the squeeze following the Royal Mail's decision to increase the price of first and second class stamps at the end of last month are being offered a helping hand by Bolton-based online parcel delivery firm Parcel2Go. The company says businesses and individuals can try to beat the Royal Mail price increase by becoming Parcel2Go users and benefiting from the vast range of reliable and cost-effective UK express delivery solutions available through the website. With just a few clicks of a mouse, customers can order delivery services from some of the ...

King Jackpot Makes Playing No Deposit Bingo a Breeze

2012-06-08
Any experienced bingo player can tell you that one of the keys to success in playing bingo online is choosing the right bingo website. Many bingo websites are all talk and no show, or do not give players the generous offers that they desire and deserve. One feature on bingo websites that every new player should look out for is no deposit required bingo. This means that when players register, they are given free cash to be used towards trying bingo games on the website, without spending a penny of their own money! While players cannot withdraw this cash for personal ...

LAST 30 PRESS RELEASES:

Post-LLM era: New horizons for AI with knowledge, collaboration, and co-evolution

“Sloshing” from celestial collisions solves mystery of how galactic clusters stay hot

Children poisoned by the synthetic opioid, fentanyl, has risen in the U.S. – eight years of national data shows

USC researchers observe mice may have a form of first aid

VUMC to develop AI technology for therapeutic antibody discovery

Unlocking the hidden proteome: The role of coding circular RNA in cancer

Advancing lung cancer treatment: Understanding the differences between LUAD and LUSC

Study reveals widening heart disease disparities in the US

The role of ubiquitination in cancer stem cell regulation

New insights into LSD1: a key regulator in disease pathogenesis

Vanderbilt lung transplant establishes new record

Revolutionizing cancer treatment: targeting EZH2 for a new era of precision medicine

Metasurface technology offers a compact way to generate multiphoton entanglement

Effort seeks to increase cancer-gene testing in primary care

Acoustofluidics-based method facilitates intracellular nanoparticle delivery

Sulfur bacteria team up to break down organic substances in the seabed

Stretching spider silk makes it stronger

Earth's orbital rhythms link timing of giant eruptions and climate change

Ammonia build-up kills liver cells but can be prevented using existing drug

New technical guidelines pave the way for widespread adoption of methane-reducing feed additives in dairy and livestock

Eradivir announces Phase 2 human challenge study of EV25 in healthy adults infected with influenza

New study finds that tooth size in Otaria byronia reflects historical shifts in population abundance

nTIDE March 2025 Jobs Report: Employment rate for people with disabilities holds steady at new plateau, despite February dip

Breakthrough cardiac regeneration research offers hope for the treatment of ischemic heart failure

Fluoride in drinking water is associated with impaired childhood cognition

New composite structure boosts polypropylene’s low-temperature toughness

While most Americans strongly support civics education in schools, partisan divide on DEI policies and free speech on college campuses remains

Revolutionizing surface science: Visualization of local dielectric properties of surfaces

LearningEMS: A new framework for electric vehicle energy management

Nearly half of popular tropical plant group related to birds-of-paradise and bananas are threatened with extinction

[Press-News.org] 76 percent of patients on oral JAK1/JAK2 inhibitor plus DMARDS achieve ACR20 response at week 12
Baricitinib demonstrates dose-dependent efficacy in active RA